Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
322.83
+4.58 (1.44%)
Jun 27, 2025, 4:00 PM - Market closed
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 24 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $335.74, which forecasts a 4% increase in the stock price over the next year. The lowest target is $220 and the highest is $500.
Price Target: $335.74 (+4%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 11 | 12 | 12 |
| Buy | 8 | 8 | 9 | 9 | 9 | 8 |
| Hold | 5 | 4 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 24 | 24 | 25 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $320 → $377 | Strong Buy | Maintains | $320 → $377 | +16.78% | Jun 26, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $300 → $360 | Buy | Maintains | $300 → $360 | +11.51% | Jun 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $330 → $338 | Buy | Maintains | $330 → $338 | +4.70% | Jun 12, 2025 |
| UBS | UBS | Strong Buy Maintains $331 → $349 | Strong Buy | Maintains | $331 → $349 | +8.11% | May 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $300 → $325 | Strong Buy | Maintains | $300 → $325 | +0.67% | May 2, 2025 |
Financial Forecast
Revenue This Year
2.94B
from 2.25B
Increased by 30.77%
Revenue Next Year
3.84B
from 2.94B
Increased by 30.51%
EPS This Year
-1.38
from -2.18
EPS Next Year
0.95
from -1.38
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2B | 5.9B | 6.9B | ||
| Avg | 2.9B | 3.8B | 4.9B | ||
| Low | 2.4B | 2.8B | 3.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.4% | 100.7% | 80.9% | ||
| Avg | 30.8% | 30.5% | 26.7% | ||
| Low | 7.9% | -6.2% | -8.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.45 | 4.84 | 9.32 | ||
| Avg | -1.38 | 0.95 | 5.56 | ||
| Low | -2.29 | -3.11 | 1.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 881.9% | ||
| Avg | - | - | 485.8% | ||
| Low | - | - | 55.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.